PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS- AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71979-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)71979-9/fulltext
Title :
PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS- AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71979-9&doi=10.1016/S1098-3015(11)71979-9
First page :
A267
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
138